EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide By Ogkologos - December 5, 2025 301 0 Facebook Twitter Google+ Pinterest WhatsApp It is a generic and hybrid of Xtandi, which has been authorised in the EU since 2013 Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR 2026 ESMO TAT Honorary Award Recipient Announced February 3, 2026 The Caregiver Curve March 15, 2021 ESMO Launches Clinical Trials Funding Initiative to Optimise Cancer Care Pathways September 10, 2026 FDA Grants Traditional Approval to Selpercatinib for RET Fusion-positive Thyroid Cancer July 2, 2024 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Capmatinib Food for thought: new insights into how chemotherapy causes cachexia COVID-19 May Have Saved a Woman’s Life by Helping Her Discover... EMA Recommends Granting a Marketing Authorisation for the Medicinal Product Nyvepria
